ZBH241220C175000
- 0.00
- 0.000.00%
Zimmer Biomet Holdings Newsroom
Zimmer Biomet Holdings (ZBH) Gets a Sell From Barclays
Citi Maintains Zimmer Biomet Holdings(ZBH.US) With Hold Rating, Maintains Target Price $120
Morgan Stanley Initiates Zimmer Biomet Holdings(ZBH.US) With Hold Rating, Announces Target Price $115
Wells Fargo Maintains Zimmer Biomet Holdings(ZBH.US) With Hold Rating, Maintains Target Price $117
Hold Rating for Zimmer Biomet Holdings Amid Uncertain Impact of New Product Launch in US Market
Truist Financial Maintains Zimmer Biomet Holdings(ZBH.US) With Hold Rating, Maintains Target Price $117
Zimmer Biomet Holdings Is Maintained at Outperform by RBC Capital
Zimmer Biomet Holdings Analyst Ratings
RBC Capital Maintains Zimmer Biomet Holdings(ZBH.US) With Buy Rating, Raises Target Price to $125
Analysts Offer Insights on Healthcare Companies: Zimmer Biomet Holdings (ZBH), Viridian Therapeutics (VRDN) and Select Medical (SEM)
Truist Financial Maintains Zimmer Biomet Holdings(ZBH.US) With Hold Rating, Announces Target Price $117
Zimmer Biomet Holdings Analyst Ratings
A Quick Look at Today's Ratings for Zimmer Biomet Holdings(ZBH.US), With a Forecast Between $117 to $140
Zimmer Biomet Holdings Is Maintained at Equal-Weight by Wells Fargo
A Quick Look at Today's Ratings for Zimmer Biomet Holdings(ZBH.US), With a Forecast Between $117 to $140
Nephron Adjusts Price Target on Zimmer Biomet to $140 From $135
Morgan Stanley Adjusts Zimmer Biomet Holdings' Price Target to $122 From $118, Keeps Equalweight Rating
JMP Securities Maintains Zimmer Biomet Holdings(ZBH.US) With Buy Rating, Maintains Target Price $140
JMP Securities Maintains Zimmer Biomet Holdings(ZBH.US) With Buy Rating, Maintains Target Price $140
Oppenheimer Maintains Zimmer Biomet Holdings(ZBH.US) With Buy Rating, Cuts Target Price to $135